NEW EVENT! Cutting-edge Trends for Life Sciences at PACK EXPO Southeast
Discover all the latest packaging solutions for life sciences products at the all-new PACK EXPO Southeast in Atlanta, GA, March 10-12, 2025

What Does a DSCSA Stabilization Period Mean?

From the HDA Traceability Seminar: FDA announced a DSCSA stabilization period through Nov. 2024 but is urging all trading partners not to take their feet off the gas. Consistent work will be needed from trading partners throughout the next 15 months.

A one-year stabilization period for DSCSA enforcement means extra time, but it's not intended to be a one-year delay in progress.
A one-year stabilization period for DSCSA enforcement means extra time, but it's not intended to be a one-year delay in progress.

The HDA Traceability Seminar opened with a packed house and a key message running through presentations: the DSCSA EDDS guidance that FDA dropped Friday, Aug. 25, is not to be looked at as simply enforcement discretion but as a stabilization period through Nov 27, 2024.

As FDA's Leigh Verbois said in her co-presentation with Connie Jung, “Let me just be really clear, we want to make sure that this time is used to implement, troubleshoot, and mature systems for trading partners and processes while supporting the continued availability of products. With the compliance policies in this new guidance, we want to focus on November 2023 and beyond.”  

Jung, FDA senior advisor for policy, reiterated the message. “This does not mean to stop doing anything. We want you to continue to implement, we expect you to continue to implement because if you don't, you will never get there,” she said. “Our expectation is that we want you to test and exchange electronic data before the date. This is what we were saying about November 2023—now, it's before November 2024, you need to be exchanging that data electronically.” 

While some may still view this as a pause, Tish Pahl, principal, Olsson Frank Weeda Terman Matz PC, highlighted a section of the guidance which is actually underlined in the EDDS guidance:

"This guidance is not intended to provide, and should not be viewed as providing, a justification for delaying efforts by trading partners to implement the enhanced drug distribution security requirements under section 582(g)(1) of the FD&C Act. FDA strongly urges trading partners to continue their efforts to implement necessary measures to satisfy these enhanced drug distribution security requirements."

As Pahl noted, "FDA doesn't use typographical arts in the way that others might... so the fact that they underlined this is actually really unusual and very important." She suggested that when dealing with companies that are calling up and canceling their contracts, show them this verbiage. 

Because of the cascading nature of an interoperable electronic system, a delay in manufacturer efforts leads to delays exchanging data with distributors/wholesalers, and then another layer of delays with dispensers. Some of those downstream trading partners expressed frustration that they’re left waiting for manufacturers to begin testing. 

Industry response

How a manufacturer uses the extra time depends on how ready they were before Friday’s guidance announcement. As LSPedia’s Riya Cao explained, “Stabilization is for companies who have already gone live, so I don't know how many of you are qualified to go into stabilization. I think a lot of people are still implementing, and then more are not even implementing yet. We’re very concerned about companies lagging behind… companies are just reading that discretion headline and making the decision not to work on this for another year. For those of you that are fortunate enough to go into stabilization, there's so much work ahead. You have to really get into the daily operations to uncover the scenarios you never thought about. Every day we're learning new things.”

Speaking on behalf of manufacturers at an onboarding panel were Blair Korman, sr. director, digital identification & traceability at Johnson & Johnson Supply Chain, and David Mason, supply chain compliance and serialization lead at Sandoz.

INTRODUCING! The Latest Trends for Life Sciences at PACK EXPO Southeast
The exciting new PACK EXPO Southeast 2025 unites all vertical markets in one dynamic hub, generating more innovative answers to packaging challenges for life sciences products. Don’t miss this extraordinary opportunity for your business!
Read More
INTRODUCING! The Latest Trends for Life Sciences at PACK EXPO Southeast